ARTICLE
9 December 2020

DOJ's $678 Million Novartis Settlement For False Claims Act And Anti-Kickback Statute Violations—Changing Big Pharma's Expectations For Compliance Programs

DOJs $678 Million Novartis Settlement for False Claims Act and Anti-Kickback Statute Violations—Changing Big Pharma's Expectations for Compliance Programs.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

Roopa Chakkappan authored an article titled, "DOJ's $678 Million Novartis Settlement for False Claims Act and Anti-Kickback Statute Violations—Changing Big Pharma's Expectations for Compliance Programs," which was posted on the American Health Law Association's (AHLA) website.  Click here to read the full article.  

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More